{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:12:50Z","timestamp":1761581570382,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.urolonc.2017.05.023","type":"journal-article","created":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T22:50:29Z","timestamp":1497653429000},"page":"462-464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Challenges and advances in the diagnosis, biology, and treatment of urothelial upper tract and bladder carcinomas"],"prefix":"10.1016","volume":"35","author":[{"given":"Jeanny B.","family":"Aragon-Ching","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2017.05.023_bib1","first-page":"7","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2017.05.023_bib2","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2017.05.023_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2017.05.023_bib4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2017.05.023_bib5","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2017.05.023_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.05.023_bib7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.2017.35.6_suppl.286","article-title":"Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma","volume":"35","author":"Powles","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.05.023_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4525","article-title":"Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC)","volume":"35","author":"Hahn","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2017.05.023_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/BLC-150037","article-title":"Bladder cancer molecular taxonomy: summary from a consensus meeting","volume":"2","author":"Lerner","year":"2016","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2017.05.023_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.urolonc.2017.03.011","article-title":"Targeted therapies in the treatment of urothelial cancers","volume":"35","author":"Aragon-Ching","year":"2017","journal-title":"Urologic Oncol"},{"key":"10.1016\/j.urolonc.2017.05.023_bib12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.urolonc.2017.05.009","article-title":"Optimizing management of upper tract urothelial cancers","volume":"35","author":"Campbell","year":"2017","journal-title":"Urologic Oncol"},{"key":"10.1016\/j.urolonc.2017.05.023_bib13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.urolonc.2017.04.014","article-title":"Advances in medical imaging for the diagnosis and management of common genitourinary cancers","volume":"35","author":"Bagheri","year":"2017","journal-title":"Urolo Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917302533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917302533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:10:55Z","timestamp":1761041455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143917302533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1078143917302533"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.05.023","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges and advances in the diagnosis, biology, and treatment of urothelial upper tract and bladder carcinomas","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}